Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

ctions and infestations, which were observed in 72% of patients on everolimus and 67% of patients on placebo(1).

EXIST-1 enrolled 117 patients in 10 countries, including the US, Poland, Russia, Germany, Belgium, Canada, Australia, Italy, the Netherlands and the UK(1,10).

About the Phase II studyIn this prospective, open-label, single-arm study, 28 patients aged three years and above (median age=11, range 3-34) with evidence of SEGA growth received a median daily dose of 5.29 mg/m2. The median treatment duration was 34.2 months (range 4.7-47.1 months). Of the 28 patients in the initial study, 27 were enrolled in the extension phase and 25 were still receiving everolimus at the extension phase cut-off date (December 31, 2010). No patients discontinued due to disease progression, adverse events or study drug use(5).

During this extension phase, reduction in SEGA volume was maintained over time and no patients required surgery or other therapy for SEGA or hydrocephalus. In the study, 78% of patients (7 of 9) who took everolimus for at least three years and 79% of patients (19 of 24) who took everolimus for at least two years experienced a reduction of 30% or greater in the size of their largest SEGA relative to baseline. Additionally, 56% of patients (5 of 9) who took everolimus for at least three years and 50% of patients (12 of 24) who took everolimus for at least two years experienced a reduction of 50% or greater in the size of their largest SEGA relative to baseline(5). These findings were consistent with those previously recorded at six months relative to baseline(2,5).

The most common AEs (all grades with an incidence of at least 20%) included: stomatitis or mouth sores (86%), upper respiratory tract infection (86%), sinusitis (47%), middle ear infection (36%), diarrhea (32%), fever (32%), cellulitis or acute infection of the deep tissues of skin or muscle (29%), convulsion (29%), gastroenteritis or inflammation of the gastrointest
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 RenovoRx ( www.renovorx.com ) ... "Top Startup" Award at TiEcon 2013, the world,s largest ... team and quality of entrepreneurial ideas. RenovoRx was honored ... Santa Clara Convention Center. ... of the most enterprising startup companies across five verticals: ...
(Date:5/21/2013)... 2013 /PRNewswire-iReach/ -- The 2013 Pharma ChemOutsourcing Show slated ... greatest number of "Emerging" small molecule biotech company ... Alexay .  "No one saw this coming", ... show,s still 4 months away and we may end ... big surprise and great news for attendees". Thecurrent list ...
(Date:5/21/2013)... 21, 2013  IsoRay, Inc. (AMEX: ISR ... entered into an exclusive international distribution agreement with IASIS ... in Greece . IsoRay is a ... medical radioisotope applications for brain cancer, lung cancer, head ... IASIS Medical is ideally suited to ...
Breaking Medicine Technology:RenovoRx Named Winner of 2013 TiE50 "Top Startup" 2Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show 2IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3
... PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 12, 2007 - ... from its Phase,2 clinical trial of Hematide(TM) ... week at the National Kidney Foundation (NKF),2007 ... trial in patients previously treated with,three-times weekly ...
... 2007--The costs of eradicating,poliomyelitis from the remaining infected ... lower than the long term costs of trying,to ... vaccine is almost three times more effective against,type ... are,the findings of two Articles published Online and ...
Cached Medicine Technology:Affymax Announces Results From Phase 2 Clinical Trial of Hematide,for the Treatment of Anemia in Dialysis Patients 2Affymax Announces Results From Phase 2 Clinical Trial of Hematide,for the Treatment of Anemia in Dialysis Patients 3Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 2Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 3
(Date:5/21/2013)... Octo Consulting Group, an award-winning ... solutions to the Federal marketplace, has named Tracy ... the newly created role, Denny will be responsible ... firm’s business development function to include business development ... leading strategies to achieve the firm’s strategic growth ...
(Date:5/21/2013)... News) -- Aggressive treatment for prostate cancer may ... underlying medical conditions, a new study finds. ... and radioactive seed implants, can cause serious side ... bowel problems, explained researchers from the University of ... that older patients with slower growing forms of ...
(Date:5/21/2013)... A study of veterans at high risk for developing ... be highly effective in helping clinicians spot tiny lung ... indicate the earliest stages of the disease. LDCT uses ... conventional CT scan. , Results of the study will ... "Lung cancer is the leading cause of cancer-related death ...
(Date:5/21/2013)... In adults with chronic kidney disease (CKD), ... CKD progression and transplant failure. Now, a first-of-its-kind study ... University has found a possible similar effect in children ... , The study of 366 children aged 1 ... effect of secondhand smoke exposure in CKD, according to ...
(Date:5/21/2013)... , , TUESDAY, May 21 (HealthDay News) -- Finding early ... but a new study adds to a growing body ... may help spot the beginnings of disease in high-risk ... risk for lung cancer, 6 percent were found to ... biopsies to confirm the diagnosis. CT scans detect abnormalities ...
Breaking Medicine News(10 mins):Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2Health News:Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary 2Health News:Low radiation scans help identify cancer in earliest stages 2Health News:Low radiation scans help identify cancer in earliest stages 3Health News:Exposure to Secondhand Smoke May Lead to Worsening of Pediatric Kidney Disease; Pediatric Nephrology Publishes Dayton Children’s, Johns Hopkins Joint Study 2Health News:Exposure to Secondhand Smoke May Lead to Worsening of Pediatric Kidney Disease; Pediatric Nephrology Publishes Dayton Children’s, Johns Hopkins Joint Study 3Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 2Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 3
... a senior citizen,s health, yet fewer than half of all seniors ... medical attention are far less likely to engage in any of ... their medications or getting a cane or walker that might ... UCLA Center for Health Policy Research. In the ...
... was true for males tying the knot with younger females, study ... men seven to nine years their junior could be upping their ... with a significantly younger guy raises a woman,s risk of death ... 12 issue of Demography . , Not that marrying much ...
... ... records between doctors is the latest expansion of the affiliation between The Mount Sinai Medical ... and most comprehensive ear, nose, and throat, allergy and audiology practice in the tri-state area. ... New York, NY (Vocus) ...
... Scientists at The Wistar Institute offer a new explanation for ... the reasons why melanoma remains the deadliest form of skin ... explain why melanoma cells behave like both conventional tumor cells ... May 14 issue of the journal Cell thatcontrary ...
... held promise for building new organs to replace damaged livers, ... is getting cells grown in a lab dish to form ... MIT-Harvard Division of Health Sciences and Technology (HST) have come ... encapsulating living cells in cubes and arranging them into 3-D ...
... will continue validating its ToxCast screening tool by ... GlaxoSmithKline, Sanofi-Aventis, and Merck. These drugs never entered ... levels of toxicity when the pharmaceutical companies conducted ... Food and Drug Administration as part of the ...
Cached Medicine News:Health News:Falls and follow-ups: Medical attention following a fall critical to senior health 2Health News:Women Who Marry Younger Men May Die Earlier 2Health News:Mount Sinai Medical Center and ENT & Allergy Associates, LLP Create First-Of-Its-Kind Physician Portal 2Health News:Mount Sinai Medical Center and ENT & Allergy Associates, LLP Create First-Of-Its-Kind Physician Portal 3Health News:Wistar scientists explain the persistence of melanoma through 'dynamic stemness' 2Health News:Wistar scientists explain the persistence of melanoma through 'dynamic stemness' 3Health News:Tissue engineers create a new way to assemble artificial tissues 2Health News:Tissue engineers create a new way to assemble artificial tissues 3Health News:Pharmaceutical companies provide EPA 100 drugs to help predict toxicity 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: